DE68928641T2 - Menschliches IFN-beta2/IL-6, dessen Reinigung und Verwendungen - Google Patents

Menschliches IFN-beta2/IL-6, dessen Reinigung und Verwendungen

Info

Publication number
DE68928641T2
DE68928641T2 DE68928641T DE68928641T DE68928641T2 DE 68928641 T2 DE68928641 T2 DE 68928641T2 DE 68928641 T DE68928641 T DE 68928641T DE 68928641 T DE68928641 T DE 68928641T DE 68928641 T2 DE68928641 T2 DE 68928641T2
Authority
DE
Germany
Prior art keywords
purification
beta2
human ifn
ifn
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68928641T
Other languages
English (en)
Other versions
DE68928641D1 (de
Inventor
Michel Revel
Menachem Rubinstein
Yves Mory
Louise Chen
Daniela Novick
Rita Michalevicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL85204A external-priority patent/IL85204A0/xx
Priority claimed from IL88376A external-priority patent/IL88376A0/xx
Priority claimed from IL8837588A external-priority patent/IL88375A/en
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE68928641D1 publication Critical patent/DE68928641D1/de
Publication of DE68928641T2 publication Critical patent/DE68928641T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE68928641T 1988-01-26 1989-01-25 Menschliches IFN-beta2/IL-6, dessen Reinigung und Verwendungen Expired - Lifetime DE68928641T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL85204A IL85204A0 (en) 1988-01-26 1988-01-26 Recombinant human interferon beta2,its preparation and pharmaceutical compositions comprising it
US19358088A 1988-05-13 1988-05-13
IL88376A IL88376A0 (en) 1988-11-14 1988-11-14 Pharmaceutical compositions containing interferon-beta 2
IL8837588A IL88375A (en) 1988-11-14 1988-11-14 Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method

Publications (2)

Publication Number Publication Date
DE68928641D1 DE68928641D1 (de) 1998-05-20
DE68928641T2 true DE68928641T2 (de) 1998-08-13

Family

ID=27452320

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68928641T Expired - Lifetime DE68928641T2 (de) 1988-01-26 1989-01-25 Menschliches IFN-beta2/IL-6, dessen Reinigung und Verwendungen

Country Status (7)

Country Link
EP (1) EP0326120B1 (de)
JP (1) JP2725818B2 (de)
AT (1) ATE165010T1 (de)
AU (1) AU621852B2 (de)
CA (1) CA1341588C (de)
DE (1) DE68928641T2 (de)
ES (1) ES2119735T3 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT92479A (pt) * 1988-12-01 1990-06-29 Univ North Carolina Processo de preparacao de genes recombinantes e suas proteinas de codificacao
JPH0331215A (ja) * 1989-06-27 1991-02-12 Ajinomoto Co Inc 制癌療法支持剤
DE3939706C1 (de) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
ES2062762T3 (es) * 1989-12-04 1994-12-16 Schering Corp Metodo para tratar el choque septico.
IT1247484B (it) * 1991-03-22 1994-12-17 Ceinge Societa Consortile A R Metodo per la preparazione di interleuchina 6
US5902576A (en) * 1992-10-22 1999-05-11 Yeda Research And Development Co. Ltd. At Weizmann Institute Of Science Antitumor pharmaceutical composition comprising IL-6 transfected cells
WO1996025433A1 (en) * 1995-02-15 1996-08-22 Mount Sinai School Of Medicine Of The City University Of New York B cell differentiation and proliferation factors and methods for obtaining and using the same
WO1997016202A1 (en) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
CA2312188C (en) 1997-12-08 2010-06-29 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DK1200479T3 (da) 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
JP4494977B2 (ja) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
DK1960430T3 (da) * 2005-12-09 2015-01-05 Ucb Pharma Sa Antistofmolekyler der har specificitet for humant il-6
PT1966238E (pt) 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
EP3348275A3 (de) 2009-03-31 2018-10-24 East Carolina University Cytokine und neuroantigene zur behandlung von immunerkrankungen
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172496A (ja) * 1983-03-18 1984-09-29 Kyowa Hakko Kogyo Co Ltd モノクロ−ナル抗体
JPH0657157B2 (ja) * 1984-11-09 1994-08-03 忠三 岸本 Ｂ細胞分化因子の製造法
IE67035B1 (en) * 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
US5198359A (en) * 1989-03-07 1993-03-30 Boehringer Ingelheim International Gmbh Recombinant protein receptor for il-2

Also Published As

Publication number Publication date
EP0326120A2 (de) 1989-08-02
AU2881389A (en) 1989-07-27
JPH029394A (ja) 1990-01-12
JP2725818B2 (ja) 1998-03-11
EP0326120A3 (de) 1990-05-02
ES2119735T3 (es) 1998-10-16
AU621852B2 (en) 1992-03-26
DE68928641D1 (de) 1998-05-20
EP0326120B1 (de) 1998-04-15
CA1341588C (en) 2009-01-06
ATE165010T1 (de) 1998-05-15

Similar Documents

Publication Publication Date Title
DE68928641D1 (de) Menschliches IFN-beta2/IL-6, dessen Reinigung und Verwendungen
PH25120A (en) Replicable expression vehicle and process of preparation thereof
DE69131699T2 (de) Verändertes menschliches iL-6
NO880929D0 (no) Produksjon og bruk av il-6.
DE69129421D1 (de) Interleukin 2 enthaltende rekombinante Immunkonjugate für die Therapie
MC1553A1 (fr) Proteine d'interferon immunitaire humain et son procede de production
DE69433648D1 (de) Menschliche chemokin-polypeptide
DE69233143D1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
MX9701330A (es) Quimiocina beta-9 humana.
DE68928710T2 (de) T-Zellen-Wachstumsfaktor
DE69130679T2 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
FI922770A0 (fi) Bcrf1-proteinerna som inhibitorer av y-interferon.
HUT59724A (en) Process for producing new thrombosolving material
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
EP0516845A4 (de) Neuer megakaryokytischer koloniestimulierender faktor und verfahren zur herstellung.
EP0672684A4 (de) Neuer megakaryot-kolonie-stimulierender faktor und seine herstellung.
JPS6452792A (en) Production of blood platelet growth factor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition